Journal Article Summary
The article investigates the risk of thromboembolism, which includes both venous thromboembolism (VTE) and arterial thromboembolism (ATE), associated with nonoral combined hormonal contraceptives (CHCs) like the patch and vaginal ring compared to traditional combined oral contraceptives (COCs). This topic is significant because while CHCs are widely used for contraception, they are also linked to increased risks of blood clots, which can lead to serious health issues. Understanding the relative risks of different contraceptive methods can help women make informed choices about their reproductive health.
The authors conducted a systematic review of existing studies published up to May 2016, focusing on research that compared the thromboembolic risks of nonoral CHCs with COCs. They identified eight studies that met their criteria, with mixed findings regarding the risk of VTE among users of the patch and ring compared to COC users. Some studies indicated a statistically significant increased risk for VTE among patch users, while others found no significant difference. For ATE, the evidence did not show an increased risk among patch users. Overall, the findings suggest that while there may be some elevated risks, they are likely small on a population level.
The review has several limitations, including reliance on studies with varying methodologies and potential biases, such as the use of insurance claims data that may not be fully accurate. Additionally, some studies did not adequately control for other risk factors for thrombosis, which could affect the results. Patients should discuss these findings with their healthcare providers to understand their individual risks and benefits when considering nonoral CHCs. It is essential to weigh these contraceptive options against the risks of unintended pregnancy and other health factors. Further research is needed to clarify the relationship between nonoral CHCs and thromboembolism.
Medication Safety Note
This journal article summary is provided for educational purposes only and is not medical advice. Always consult a licensed healthcare professional before starting, stopping, or changing any medication.
Article Cited
- Tepper Naomi K., Dragoman Monica V., Gaffield Mary E., Curtis Kathryn M.. Nonoral combined hormonal contraceptives and thromboembolism: a systematic review. Contraception 2017. DOI: 10.1016/j.contraception.2016.10.005. PMID: 27771476. PMCID: PMC11025291.
Featured Pill Pals Product
OPill (O-Pill) Norgestrel Tablets 0.075 mg Daily Oral Contraceptive --- Perrigo
OPill (O-Pill) Norgestrel Tablets 0.075 mg Daily Oral Contraceptive --- Perrigo is available through Pill Pals Pharmacy with cash-pay pharmacy pricing and free shipping where available. No prescription required for eligible over-the-counter purchases.
